IPA — Immunoprecise Antibodies Cashflow Statement
0.000.00%
Last trade - 00:00- $21.01m
- $21.02m
- CA$24.52m
- 46
- 47
- 54
- 47
Annual cashflow statement for Immunoprecise Antibodies, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.95 | -7.34 | -16.7 | -26.6 | -27.2 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.72 | 4.13 | 2.77 | 4.24 | 16.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.12 | -1.02 | 0.582 | -3.28 | 2.37 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -1.39 | -0.6 | -9.92 | -19.8 | -4.25 |
| Capital Expenditures | -0.488 | -1.38 | -1.07 | -1.5 | -1.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -1.1 | -1.08 | -4.14 | -0.472 | -0.166 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.58 | -2.46 | -5.21 | -1.97 | -1.56 |
| Financing Cash Flow Items | 0 | — | -0.005 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.175 | 43.4 | 2.88 | -0.621 | 1.02 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.85 | 39.1 | -11.8 | -21.7 | -4.82 |